|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MBIP |
Gene summary for MBIP |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MBIP | Gene ID | 51562 |
| Gene name | MAP3K12 binding inhibitory protein 1 | |
| Gene Alias | MBIP | |
| Cytomap | 14q13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q9NS73 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51562 | MBIP | LZE2T | Human | Esophagus | ESCC | 1.25e-04 | 2.98e-01 | 0.082 |
| 51562 | MBIP | LZE4T | Human | Esophagus | ESCC | 3.16e-23 | 6.40e-01 | 0.0811 |
| 51562 | MBIP | LZE5T | Human | Esophagus | ESCC | 1.61e-05 | 4.21e-01 | 0.0514 |
| 51562 | MBIP | LZE7T | Human | Esophagus | ESCC | 1.51e-04 | 7.81e-02 | 0.0667 |
| 51562 | MBIP | LZE8T | Human | Esophagus | ESCC | 6.74e-06 | 1.16e-01 | 0.067 |
| 51562 | MBIP | LZE20T | Human | Esophagus | ESCC | 2.81e-06 | 1.23e-01 | 0.0662 |
| 51562 | MBIP | LZE22T | Human | Esophagus | ESCC | 9.76e-05 | 4.21e-01 | 0.068 |
| 51562 | MBIP | LZE24T | Human | Esophagus | ESCC | 7.29e-19 | 2.31e-01 | 0.0596 |
| 51562 | MBIP | LZE6T | Human | Esophagus | ESCC | 1.53e-05 | 1.18e-01 | 0.0845 |
| 51562 | MBIP | P2T-E | Human | Esophagus | ESCC | 6.61e-21 | 3.09e-01 | 0.1177 |
| 51562 | MBIP | P4T-E | Human | Esophagus | ESCC | 5.81e-11 | 2.98e-01 | 0.1323 |
| 51562 | MBIP | P5T-E | Human | Esophagus | ESCC | 3.21e-20 | 3.58e-01 | 0.1327 |
| 51562 | MBIP | P8T-E | Human | Esophagus | ESCC | 1.14e-69 | 1.21e+00 | 0.0889 |
| 51562 | MBIP | P9T-E | Human | Esophagus | ESCC | 3.27e-13 | 2.27e-01 | 0.1131 |
| 51562 | MBIP | P10T-E | Human | Esophagus | ESCC | 8.86e-35 | 6.51e-01 | 0.116 |
| 51562 | MBIP | P11T-E | Human | Esophagus | ESCC | 3.06e-12 | 5.13e-01 | 0.1426 |
| 51562 | MBIP | P12T-E | Human | Esophagus | ESCC | 7.10e-73 | 1.54e+00 | 0.1122 |
| 51562 | MBIP | P15T-E | Human | Esophagus | ESCC | 1.75e-41 | 8.41e-01 | 0.1149 |
| 51562 | MBIP | P16T-E | Human | Esophagus | ESCC | 1.42e-15 | 2.57e-01 | 0.1153 |
| 51562 | MBIP | P17T-E | Human | Esophagus | ESCC | 2.57e-04 | 2.84e-01 | 0.1278 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003109816 | Oral cavity | OSCC | stress-activated protein kinase signaling cascade | 141/7305 | 247/18723 | 5.74e-09 | 1.25e-07 | 141 |
| GO:005140316 | Oral cavity | OSCC | stress-activated MAPK cascade | 134/7305 | 239/18723 | 6.02e-08 | 1.09e-06 | 134 |
| GO:007030210 | Oral cavity | OSCC | regulation of stress-activated protein kinase signaling cascade | 111/7305 | 195/18723 | 2.82e-07 | 4.34e-06 | 111 |
| GO:003287210 | Oral cavity | OSCC | regulation of stress-activated MAPK cascade | 108/7305 | 192/18723 | 8.97e-07 | 1.22e-05 | 108 |
| GO:00072548 | Oral cavity | OSCC | JNK cascade | 90/7305 | 167/18723 | 6.49e-05 | 5.26e-04 | 90 |
| GO:00463288 | Oral cavity | OSCC | regulation of JNK cascade | 74/7305 | 133/18723 | 7.22e-05 | 5.69e-04 | 74 |
| GO:00439661 | Oral cavity | OSCC | histone H3 acetylation | 36/7305 | 61/18723 | 1.21e-03 | 6.10e-03 | 36 |
| GO:00703045 | Oral cavity | OSCC | positive regulation of stress-activated protein kinase signaling cascade | 66/7305 | 128/18723 | 2.58e-03 | 1.13e-02 | 66 |
| GO:00328744 | Oral cavity | OSCC | positive regulation of stress-activated MAPK cascade | 64/7305 | 126/18723 | 4.67e-03 | 1.87e-02 | 64 |
| GO:00434107 | Oral cavity | OSCC | positive regulation of MAPK cascade | 213/7305 | 480/18723 | 8.71e-03 | 3.16e-02 | 213 |
| GO:00463301 | Oral cavity | OSCC | positive regulation of JNK cascade | 46/7305 | 89/18723 | 1.01e-02 | 3.50e-02 | 46 |
| GO:001657024 | Skin | cSCC | histone modification | 179/4864 | 463/18723 | 9.65e-10 | 3.74e-08 | 179 |
| GO:000647314 | Skin | cSCC | protein acetylation | 84/4864 | 201/18723 | 6.94e-07 | 1.29e-05 | 84 |
| GO:001839414 | Skin | cSCC | peptidyl-lysine acetylation | 72/4864 | 169/18723 | 1.81e-06 | 3.02e-05 | 72 |
| GO:001820515 | Skin | cSCC | peptidyl-lysine modification | 137/4864 | 376/18723 | 4.09e-06 | 6.09e-05 | 137 |
| GO:004354314 | Skin | cSCC | protein acylation | 95/4864 | 243/18723 | 4.56e-06 | 6.71e-05 | 95 |
| GO:000647514 | Skin | cSCC | internal protein amino acid acetylation | 66/4864 | 160/18723 | 1.72e-05 | 2.07e-04 | 66 |
| GO:001839314 | Skin | cSCC | internal peptidyl-lysine acetylation | 65/4864 | 158/18723 | 2.19e-05 | 2.54e-04 | 65 |
| GO:001657313 | Skin | cSCC | histone acetylation | 62/4864 | 152/18723 | 4.54e-05 | 4.75e-04 | 62 |
| GO:003109825 | Skin | cSCC | stress-activated protein kinase signaling cascade | 92/4864 | 247/18723 | 5.78e-05 | 5.74e-04 | 92 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MBIP | SNV | Missense_Mutation | novel | c.558N>G | p.Ile186Met | p.I186M | Q9NS73 | protein_coding | tolerated(0.06) | probably_damaging(0.951) | TCGA-E9-A54X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MBIP | SNV | Missense_Mutation | rs764812440 | c.557N>C | p.Ile186Thr | p.I186T | Q9NS73 | protein_coding | deleterious(0) | possibly_damaging(0.791) | TCGA-E9-A54X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MBIP | SNV | Missense_Mutation | novel | c.145N>A | p.Asp49Asn | p.D49N | Q9NS73 | protein_coding | tolerated(0.17) | probably_damaging(0.922) | TCGA-WT-AB41-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| MBIP | insertion | Frame_Shift_Ins | novel | c.889-1_889insCAACCGGAGTTTTCAGGTGGGTTACAGA | p.Ser297GlnfsTer29 | p.S297Qfs*29 | Q9NS73 | protein_coding | TCGA-AO-A0J5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate | zoledronic | PD | ||
| MBIP | deletion | Frame_Shift_Del | novel | c.264delN | p.Lys88AsnfsTer17 | p.K88Nfs*17 | Q9NS73 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| MBIP | SNV | Missense_Mutation | novel | c.101N>C | p.Phe34Ser | p.F34S | Q9NS73 | protein_coding | tolerated(0.1) | benign(0.069) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MBIP | SNV | Missense_Mutation | novel | c.133N>C | p.Asp45His | p.D45H | Q9NS73 | protein_coding | deleterious(0.01) | benign(0.132) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
| MBIP | SNV | Missense_Mutation | c.257T>C | p.Leu86Ser | p.L86S | Q9NS73 | protein_coding | tolerated(0.23) | probably_damaging(0.97) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MBIP | SNV | Missense_Mutation | c.844A>G | p.Ile282Val | p.I282V | Q9NS73 | protein_coding | tolerated(0.05) | possibly_damaging(0.472) | TCGA-F5-6813-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
| MBIP | deletion | Frame_Shift_Del | c.257delN | p.Leu86Ter | p.L86* | Q9NS73 | protein_coding | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |